肝病市场－全球产业规模、份额、趋势、机会和预测，依治疗类型、疾病类型、地区和竞争格局划分，2020-2030年预测

2024年全球肝病市场规模为121.8亿美元，预计2030年将以8.6%的复合年增长率成长至199.8亿美元。全球肝病市场涵盖肝臟、胆囊、胆道系统和胰臟疾病的研究、预防、诊断和治疗，包括病毒性肝炎、肝硬化、脂肪肝和肝细胞癌等。该市场的成长主要受以下因素驱动：全球肝臟疾病盛行率不断上升、公众对肝臟健康的认识不断提高以及诊断方法的持续进步。

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：客户之声

第五章：全球肝病市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依治疗类型（抗病毒药物、疫苗、免疫抑制剂、标靶治疗、化疗、皮质类固醇、免疫球蛋白）
  • 依疾病类型（肝炎、肝癌、遗传性疾病、自体免疫疾病、非酒精性脂肪肝疾病、其他）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美肝病市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲肝病市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太肝病市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东与非洲肝病市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲肝病市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购（如有）
• 产品发布（如有）
• 最新进展

第十三章：全球肝病市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Astellas Pharma Inc.
• Merck & Co. Inc.
• Abbott Laboratories, Inc.
• Bristol- Myers Squibb Company
• AbbVie Inc.
• Emergent BioSolutions Inc.
• F. Hoffmann- La Roche AG
• Eli Lilly and Company
• Viatris Inc.
• Gilead Sciences, Inc.

第十六章：策略建议

第17章调查会社について・免责事项

The Global Hepatology Market, valued at USD 12.18 Billion in 2024, is projected to experience a CAGR of 8.6% to reach USD 19.98 Billion by 2030. The global hepatology market encompasses the study, prevention, diagnosis, and management of diseases affecting the liver, gallbladder, biliary tree, and pancreas, including conditions such as viral hepatitis, liver cirrhosis, fatty liver disease, and hepatocellular carcinoma. This market's expansion is primarily driven by the escalating global prevalence of liver disorders, heightened public awareness regarding liver health, and continuous advancements in diagnostic methodologies.

Key Market Drivers

The increasing prevalence of liver diseases is a primary driver expanding the global hepatology market. Conditions like Non-Alcoholic Fatty Liver Disease are rising significantly, fueled by evolving dietary patterns and sedentary lifestyles. This widespread increase in patient populations directly generates greater demand for diagnostic tools, monitoring, and therapeutic interventions. According to "Worldwide burden of non-alcoholic fatty liver disease, 1990-2021: a systematic analysis of the Global Burden of Disease Study 2021" published on ResearchGate, in November 2024, an estimated 1.27 billion people were affected by NAFLD in 2021, highlighting this condition's immense burden on global health systems.

Key Market Challenges

The high cost associated with advanced treatments presents a notable challenge for the global hepatology market. These substantial expenses frequently lead to restricted patient access, particularly in healthcare systems with stringent reimbursement policies or where individuals incur a significant proportion of out-of-pocket costs. The considerable financial strain placed on patients, healthcare providers, and payers can delay or prevent the widespread adoption of essential, innovative therapies, irrespective of their proven clinical efficacy. According to a 2024 study published in the Journal of Managed Care & Specialty Pharmacy, the mean annual healthcare costs per person were approximately $110,403 for patients diagnosed with cirrhosis, a severe liver condition, compared to $28,340 for those without cirrhosis.

Key Market Trends

Strategic Partnerships and Mergers for Pipeline Enhancement represent a crucial trend, as pharmaceutical and biotechnology companies seek to strengthen their portfolios and accelerate the development of novel liver disease treatments. These collaborations enable firms to share risks, leverage diverse expertise, and gain access to promising drug candidates, thereby expanding their market reach and competitive advantage. According to IQVIA, biopharma merger and acquisition activity in 2023 experienced a 79% increase in aggregate deal value compared to 2022, reaching approximately $152 billion, indicating robust investment in pipeline expansion across the biopharmaceutical sector.

Key Market Players

• Astellas Pharma Inc.
• Merck & Co. Inc.
• Abbott Laboratories, Inc.
• Bristol- Myers Squibb Company
• AbbVie Inc.
• Emergent BioSolutions Inc.
• F. Hoffmann- La Roche AG
• Eli Lilly and Company
• Viatris Inc.
• Gilead Sciences, Inc.

Report Scope:

In this report, the Global Hepatology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hepatology Market, By Treatment Type:

• Antiviral Drugs
• Vaccines
• Immunosuppressants
• Targeted Therapy
• Chemotherapy
• Corticosteroids
• Immunoglobulins

Hepatology Market, By Disease Type:

• Hepatitis
• Liver Cancer
• Genetic Disorders
• Autoimmune Diseases
• Non- Alcoholic Fatty Liver Diseases
• Others

Hepatology Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Hepatology Market.

Available Customizations:

Global Hepatology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Hepatology Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment Type (Antiviral Drugs, Vaccines, Immunosuppressants, Targeted Therapy, Chemotherapy, Corticosteroids, Immunoglobulins)
  • 5.2.2. By Disease Type (Hepatitis, Liver Cancer, Genetic Disorders, Autoimmune Diseases, Non- Alcoholic Fatty Liver Diseases, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Hepatology Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment Type
  • 6.2.2. By Disease Type
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Hepatology Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment Type
      • 6.3.1.2.2. By Disease Type
  • 6.3.2. Canada Hepatology Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment Type
      • 6.3.2.2.2. By Disease Type
  • 6.3.3. Mexico Hepatology Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment Type
      • 6.3.3.2.2. By Disease Type

7. Europe Hepatology Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment Type
  • 7.2.2. By Disease Type
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Hepatology Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment Type
      • 7.3.1.2.2. By Disease Type
  • 7.3.2. France Hepatology Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment Type
      • 7.3.2.2.2. By Disease Type
  • 7.3.3. United Kingdom Hepatology Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment Type
      • 7.3.3.2.2. By Disease Type
  • 7.3.4. Italy Hepatology Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment Type
      • 7.3.4.2.2. By Disease Type
  • 7.3.5. Spain Hepatology Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment Type
      • 7.3.5.2.2. By Disease Type

8. Asia Pacific Hepatology Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment Type
  • 8.2.2. By Disease Type
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Hepatology Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment Type
      • 8.3.1.2.2. By Disease Type
  • 8.3.2. India Hepatology Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment Type
      • 8.3.2.2.2. By Disease Type
  • 8.3.3. Japan Hepatology Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment Type
      • 8.3.3.2.2. By Disease Type
  • 8.3.4. South Korea Hepatology Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment Type
      • 8.3.4.2.2. By Disease Type
  • 8.3.5. Australia Hepatology Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment Type
      • 8.3.5.2.2. By Disease Type

9. Middle East & Africa Hepatology Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment Type
  • 9.2.2. By Disease Type
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Hepatology Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment Type
      • 9.3.1.2.2. By Disease Type
  • 9.3.2. UAE Hepatology Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment Type
      • 9.3.2.2.2. By Disease Type
  • 9.3.3. South Africa Hepatology Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment Type
      • 9.3.3.2.2. By Disease Type

10. South America Hepatology Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment Type
  • 10.2.2. By Disease Type
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Hepatology Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment Type
      • 10.3.1.2.2. By Disease Type
  • 10.3.2. Colombia Hepatology Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment Type
      • 10.3.2.2.2. By Disease Type
  • 10.3.3. Argentina Hepatology Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment Type
      • 10.3.3.2.2. By Disease Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Hepatology Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Astellas Pharma Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Merck & Co. Inc.
• 15.3. Abbott Laboratories, Inc.
• 15.4. Bristol- Myers Squibb Company
• 15.5. AbbVie Inc.
• 15.6. Emergent BioSolutions Inc.
• 15.7. F. Hoffmann- La Roche AG
• 15.8. Eli Lilly and Company
• 15.9. Viatris Inc.
• 15.10. Gilead Sciences, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer